Zentalis Pharmaceuticals, Inc. (ZNTL)
| Market Cap | 288.33M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -137.06M |
| Shares Out | 70.93M |
| EPS (ttm) | -1.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,179,923 |
| Open | 4.250 |
| Previous Close | 4.250 |
| Day's Range | 3.930 - 4.310 |
| 52-Week Range | 1.130 - 6.950 |
| Beta | 1.66 |
| Analysts | Buy |
| Price Target | 6.60 (+62.36%) |
| Earnings Date | May 13, 2026 |
About ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ZNTL stock is "Buy." The 12-month stock price target is $6.6, which is an increase of 62.36% from the latest price.
News
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer
Results from Part 1 of the Phase 1b MUIR trial to be presented at annual meeting in June Results from Part 1 of the Phase 1b MUIR trial to be presented at annual meeting in June
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhi...
What's Behind The Surge In Zentalis Stock?
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) shares are surging Friday after a Guggenheim analyst raised the price target from $6 to $10.
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles between the two dose groups Azenosertib ther...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhi...
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
On track for DENALI Part 2a dose confirmation in 1H 2026 DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approval On track to initiate the ASPENOVA Phas...
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhi...
Zentalis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Azenosertib is advancing in platinum-resistant ovarian cancer, with DENALI Part 2 and the ASPENOVA phase 3 trial targeting high cyclin E1 patients. Consistent response rates above 30% and manageable safety support regulatory ambitions, while expansion into earlier lines and combination strategies is underway.
Zentalis Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Azenosertib is advancing in late-stage trials for PROC patients with high Cyclin E1 expression, targeting a 21,500-patient market in the US, EU4, and UK. The DENALI and ASPENOVA trials are on track, with consistent efficacy, manageable safety, and regulatory alignment for accelerated approval.
Zentalis Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Leadership is advancing azenosertib as a first oral, non-chemo option for PROC, with pivotal DENALI and ASPENOVA trials underway. The drug targets Cyclin E1 positive patients, offering improved quality of life and manageable safety, with regulatory alignment for accelerated and full approval.
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhib...
Zentalis Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Azenosertib is advancing through pivotal trials for platinum-resistant ovarian cancer with high cyclin E1, using a biomarker-driven approach and adaptive trial designs to accelerate approval. The drug shows a favorable safety profile and differentiation from existing therapies, with future plans for combinations and potential expansion into other indications.
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference
SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhib...
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026
Completed enrollment in DENALI Part 2a; dose confirmation expected in 1H 2026 DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approval Initiation of the...
Zentalis Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference
Azenosertib demonstrates strong efficacy and safety in Cyclin E1-positive PROC, with a phase two trial underway and a phase three confirmatory study planned for 2026. The companion diagnostic is ready, and robust site activation supports global enrollment.
Zentalis Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Azenosertib is advancing as a differentiated, oral therapy for platinum-resistant ovarian cancer, with strong response rates and a favorable safety profile. The DENALI trial is on track for top-line data by end of 2026, and combination strategies are being explored for broader impact.
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated appro...
Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Presentations feature data from first-in-human Phase 1 study including Cyclin E1 biomarker findings, supporting late-stage development of azenosertib Presentations feature data from first-in-human Pha...
Zentalis Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Azenosertib is being advanced in platinum-resistant ovarian cancer with a focus on cyclin E1 biomarker selection, showing promising response rates and durability. The Denali trial is on track for accelerated approval, with FDA alignment and a strong cash position supporting development through late 2027.
Zentalis Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Azenosertib demonstrates strong efficacy and tolerability in cyclin E1 positive platinum-resistant ovarian cancer, with a registration trial underway and top-line data expected by late 2026. The company is well-funded through 2027 and plans to expand into additional indications if successful.
Zentalis Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Azenasertib is advancing as a first-in-class, non-chemo oral therapy for cyclin E1 overexpressing, platinum-resistant ovarian cancer, with a focus on accelerated approval and strong market potential. Ongoing trials compare 300mg and 400mg doses, with top-line data expected by end of 2026.
Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary
Seasoned life sciences legal executive brings extensive public company experience, including broad strategic and financial transaction expertise Seasoned life sciences legal executive brings extensive...
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated appro...
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 i...
Zentalis Pharmaceuticals Transcript: Jefferies Global Life Sciences Conference
Azenosertib, a WEE1 inhibitor, is advancing in late-stage trials for Cyclin E1-positive PROC, targeting a significant unmet need with a biomarker-driven approach. Robust clinical data show over 30% response rates and manageable safety, with top-line phase 2 data expected by end of 2026. Expansion into other tumor types is being explored, but the primary focus remains on PROC.